HER2 overexpression and activation, and tamoxifen efficacy in receptor-positive early breast cancer

Journal of Cancer Research and Clinical Oncology

Volumn 135, Issue 6, 2009, Pages 807-813

  Singer, Christian F ^a,d   Gschwantler Kaulich, Daphne ^a   Fink Retter, Anneliese ^a   Pfeiler, Georg ^a   Walter, Ingrid ^b   Hudelist, Gernot ^a,c   Helmy, Samir ^a   Spiess, Anne Catherine ^a   Lamm, Wolfgang ^a   Kubista, Ernst ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF VETERINARY MEDICINE   (Austria)

^c LKH Villach ^*  (Austria)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Breast cancer; Her2; Tamoxifen efficacy

Indexed keywords

AROMATASE INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; DISEASE SEVERITY; DRUG EFFICACY; EARLY CANCER; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TAMOXIFEN; TIME FACTORS; TREATMENT OUTCOME;

EID: 67349198443     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00432-008-0516-x     Document Type: Article

References (26)

1. M Bilous C Ades J Armes J Bishop R Brown B Cooke M Cummings G Farshid A Field A Morey P McKenzie W Raymond P Robbins L Tan 2003 Predicting the HER2 status of breast cancer from basic histopathology data: an analysis of 1,500 breast cancers as part of the HER2000 international study Breast 12 2 92 98 10.1016/S0960-9776(02)00273-4
2. P Birner G Oberhuber J Stani C Reithofer H Samonigg H Hausmaninger E Kubista W Kwasny D Kandioler-Eckersberger M Gnant R Jakesz 2001 Austrian breast and colorectal cancer study group. Evaluation of the United States food and drug administration-approved scoring and test system of HER-2 protein expression in breast cancer Clin Cancer Res 7 6 1669 1675
3. DK Biswas AP Cruz E Gansberger AB Pardee 2000 Epidermal growth factor-induced nuclear factor kappa B activation: a major pathway of cell-cycle progression in estrogen-receptor negative breast cancer cells Proc Natl Acad Sci USA 97 8542 8547 10.1073/pnas.97.15.8542
4. D Ciocca F Fujimura A Tandon G Clark C Mark G Lee-Chen G Pounds P Vendely M Owens M Pandian 1992 Correlation ofHER-2/neu amplificationwith expression and with other prognostic factors in 1,103 breast cancers J Natl Cancer Inst 84 1279 1282 10.1093/jnci/84.16.1279
5. Early Breast Cancer Trialists' Collaborative Group (1998) Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351(9114):1451-1467. doi: 10.1016/S0140-6736(97)11423-4
6. MJ Ellis A Coop B Singh L Mauriac A Llombert-Cussac F Jänicke WR Miller DB Evans M Dugan C Brady E Quebe-Fehling M Borgs 2001 Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial J Clin Oncol 19 18 3808 3816
7. JM Gee JF Robertson E Gutteridge IO Ellis SE Pinder M Rubini RI Nicholson 2005 Epidermal growth factor receptor/HER2/insulin-like growth factor receptor signalling and oestrogen receptor activity in clinical breast cancer Endocr Relat Cancer 12 Suppl 1 S99 S111 10.1677/erc.1.01005
8. JN Holloway S Murthy D El-Ashry 2004 A cytoplasmic substrate of mitogen-activated protein kinase is responsible for estrogen receptor-alpha down-regulation in breast cancer cells: the role of nuclear factor-kappa B Mol Endocrinol 18 1396 1410 10.1210/me.2004-0048
9. HJ Huang P Neven M Drijkoningen R Paridaens H Wildiers E Van Limbergen P Berteloot F Amant I Vergote MR Christiaens 2005 Hormone receptors do not predict the HER2/neu status in all age groups of women with an operable breast cancer Ann Oncol 16 11 1755 1761 10.1093/annonc/mdi364
10. G Konecny G Pauletti M Pegram M Untch S Dandekar Z Aguilar C Wilson HM Rong I Bauerfeind M Felber 2003 Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer J Natl Cancer Inst 95 142 153
11. S Massarweh CK Osborne J Shou AE Wakeling M Rimawi SK Mohsin S Hilsenbeck R Schiff 2006 Mechanisms of tumour regression and resistance to estrogen deprivation and fulvestrant in a model of estrogen receptor-positive, Her-2 breast cancer Cancer Res 66 8266 8273 10.1158/0008-5472.CAN-05-4045
12. S Massarweh CK Osborne CJ Creighton L Qin A Tsimelzon S Huang H Weiss M Rimawi R Schiff 2008 Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function Cancer Res 68 3 826 833 10.1158/0008-5472.CAN-07-2707
13. S Ménard S Fortis F Castiglioni R Agresti A Balsari 2001 HER2 as a prognostic factor in breast cancer Oncology 61 Suppl 2 67 72 10.1159/000055404
14. CK Osborne J Shou S Massarweh R Schiff 2005 Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer Clin Cancer Res 11 2 Pt 2 865s 870s
15. MA Owens BC Horten MM Da Silva 2004 HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6,556 breast cancer tissues Clin Breast Cancer 5 63 69 10.3816/CBC.2004.n.011
16. A Reiner B Neumeister J Spona G Reiner M Schemper R Jakesz 1990 Immunocytochemical localization of estrogen and progesterone receptor and prognosis in human primary breast cancer Cancer Res 50 21 7057 7061
17. R Schiff SA Massarweh J Shou L Bharwani G Arpino M Rimawi CK Osborne 2005 Advanced concepts in estrogen receptor biology and breast cancer endocrine resistance: implicated role of growth factor signaling and estrogen receptor coregulators Cancer Chemother Pharmacol 56 Suppl 1 10 20 10.1007/s00280-005- 0108-2
18. J Shou S Massarweh CK Osborne AE Wakeling S Ali H Weiss R Schiff 2004 Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer J Natl Cancer Inst 96 12 926 935
19. Singer CF, Köstler WJ, Hudelist G (2008) Predicting the efficacy of trastuzumab-based therapy in breast cancer: current standards and future strategies. Biochim Biophys Acta [epub ahead of print]
20. DJ Slamon GM Clark SG Wong 1987 Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene Science 235 177 182 10.1126/science.3798106
21. DJ Slamon W Godolphin LA Jones 1989 Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer Science 244 707 712 10.1126/science.2470152
22. A Stoica M Saceda A Fakhro M Joyner MB Martin 2000 Role of insulin-like growth factor-I in regulating estrogen receptor-alpha gene expression J Cell Biochem 76 605 614 10.1002/(SICI)1097-4644(20000315)76:4<605::AID-JCB9>3. 0.CO;2-T
23. C Tang C Perez T Grunt C Waibel C Cho R Lupu 1996 Involvement of heregulin-beta2 in the acquisition of the hormone-independent phenotype of breast cancer cells Cancer Res 56 3350 3358
24. S Taucher M Rudas RM Mader M Gnant P Dubsky S Roka T Bachleitner D Kandioler G Steger M Mittlböck R Jakesz 2004 Prognostic markers in breast cancer: the reliability of HER2/neu status in core needle biopsy of 325 patients with primary breast cancer Wien Klin Wochenschr 116 1-2 26 31
25. H Yaziji LC Goldstein TS Barry 2004 HER-2 testing in breast cancer using parallel tissue-based methods JAMA 291 1972 1977 10.1001/jama.291.16.1972
26. R Zeillinger F Kury K Czerwenka E Kubista G Sliutz W Knogler J Huber C Zielinski G Reiner R Jakesz 1989 HER-2 amplification, steroid receptors and epidermal growth factor receptor in primary breast cancer Oncogene 4 109 114